Recently, human EphA4-Fc was mutated by our group using a novel glycoengineering method to greatly enhance its half-life without affecting its other characteristics9, enabling it to be developed as a potential treatment for ALS and other diseases where long-term treatment would be required. The gene discussed is EPHA4; the disease is amyotrophic lateral sclerosis.